Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.39 (market cap $950.14M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 7.9× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Innov-100 0DTE Covered Call Strat ETF for 59 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QDTE | SYRE | |
|---|---|---|
Market Cap | $950.14M | $7.52B |
Volume | 170,009 | 1,441,031 |
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $108.92 |
52-Week Low | $26.85 | $22.18 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.29, down 0.14% with a bearish technical signal. The fund provides weekly distributions but faces criticism for yield sustainability and NAV erosion. Recent dividend payments have declined from $0.28 to $0.11, reflecting volatility compression. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
Outlook remains cautious due to structural concerns about return-of-capital distributions and underperformance in bull markets. The 24-31% yield appears unsustainable, with the fund sacrificing upside potential. Key risks include NAV decay, fee drag, and dependence on market volatility. Analyst sentiment has turned neutral to negative on the strategy's long-term viability.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
